GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants

Phase 1

Active, not recruiting

Conditions: Diarrhoea

Interventions: Biological: altSonflex1-2-3 Dose C
Biological: GSK's Meningococcal A, C, Y and W-135 conjugate vaccine
Biological: altSonflex1-2-3 Dose A
Biological: altSonflex1-2-3 Dose B
Drug: altSonflex Placebo
Combination Product: GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine
Combination Product: GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
Combination Product: Sanofi Pasteur's Typhoid Vi polysaccharide vaccine
Biological: Serum Institute of India's Measles and rubella vaccine

First Posted Date: 2021-10-11

Last Posted Date: 2025-03-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 552

Registration Number: NCT05073003

Locations: 🇰🇪
GSK Investigational Site, Kericho, Kenya

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin

First Posted Date: 2021-10-01

Last Posted Date: 2025-02-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 177

Registration Number: NCT05064358

Locations: 🇬🇧
GSK Investigational Site, Stoke on Trent, United Kingdom

A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above

Phase 3

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSVPreF3 OA investigational vaccine

First Posted Date: 2021-09-28

Last Posted Date: 2023-02-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 770

Registration Number: NCT05059301

Locations: 🇸🇪
GSK Investigational Site, Uppsala, Sweden

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

Phase 3

Completed

Conditions: Herpes Zoster

Interventions: Biological: HZ/su
Combination Product: Flu D-QIV
Biological: mRNA-1273

First Posted Date: 2021-09-17

Last Posted Date: 2023-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2013

Registration Number: NCT05047770

Locations: 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

Phase 3

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Combination Product: RSVPreF3(120 μg)
Combination Product: Flu Quadrivalent influenza vaccine (15 μg HA)
Combination Product: Placebo